Navuridine - CAS 84472-85-5
Catalog number: 84472-85-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C9H11N5O4
Molecular Weight:
253.22
COA:
Inquire
Targets:
DNA/RNA Synthesis
Description:
Navuridine is a RNA-directed DNA polymerase inhibitor under the development of Bayer HealthCare Pharmaceuticals. But research for the teatment of HIV infections was discontinued.
Purity:
98%
Appearance:
Powder
Synonyms:
1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; 3’-Azido-2’,3’-dideoxyuridine
Solubility:
Soluble in DMSO
Storage:
-20℃ Freezer
MSDS:
Inquire
Application:
HIV infections
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
ZSNNBSPEFVIUDS-SHYZEUOFSA-N
InChI:
InChI=1S/C9H11N5O4/c10-13-12-5-3-8(18-6(5)4-15)14-2-1-7(16)11-9(14)17/h1-2,5-6,8,15H,3-4H2,(H,11,16,17)/t5-,6+,8+/m0/s1
Canonical SMILES:
C1C(C(OC1N2C=CC(=O)NC2=O)CO)N=[N+]=[N-]
Current Developer:
Bayer HealthCare Pharmaceuticals
1.Determination of 3'-azido-2',3'-dideoxyuridine in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography.
Clark TN;White CA;Chu CK;Bartlett MG J Chromatogr B Biomed Sci Appl. 2001 May 5;755(1-2):165-72.
3'-Azido-2',3'-dideoxyuridine (AZDU, Azddu, CS-87) is a nucleoside analog of 3'-azido-3'-deoxythymidine (zidovudine, AZT) that has been shown to inhibit human immunodeficiency virus (HIV-1). AZDU is a potential candidate for treatment of pregnant mothers to prevent prenatal transmission of HIV/AIDS to their unborn children. A rapid and efficient high-performance liquid chromatography (HPLC) method for the determination of AZDU concentrations in rat maternal plasma, amniotic fluid, placental and fetal tissue samples has been developed and validated. Tissue samples were homogenized in distilled water, protein precipitated and extracted using a C-18 solid-phase extraction (SPE) method prior to analysis. Plasma and amniotic fluid samples were protein precipitated with 2 M perchloric acid prior to analysis. Baseline resolution was achieved using a 4.5% acetonitrile in 40 mM sodium acetate (pH 7) buffer mobile phase for amniotic fluid, placenta and fetus samples and with a 5.5% acetonitrile in buffer solution for plasma at flow-rates of 2.0 ml/min. The HPLC system consists of a Hypersil ODS column (150x4.6 mm) with a Nova-Pak C-18 guard column with detection at 263 nm. The method yields retention times of 6.
2.Nucleoside conjugates. 15. Synthesis and biological activity of anti-HIV nucleoside conjugates of ether and thioether phospholipids.
Hong CI;Nechaev A;Kirisits AJ;Vig R;West CR;Manouilov KK;Chu CK J Med Chem. 1996 Apr 26;39(9):1771-7.
A series of the anti-HIV nucleoside conjugates of either (1-O-alkyl) and thioether (1-S-alkyl) lipids linked by a pyrophosphate diester bond has been synthesized as micelle-forming prodrugs of the nucleosides to improve their therapeutic efficiency. These include AZT 5'-diphosphate-rac-1-S-octadecyl-2-O-palmitoyl-1-thioglycerol (1), 3'-azido-2',3'-dideoxyuridine 5'-diphosphate-rac-1-S-octadecyl-2-O-palmitoyl-1-thioglycerol (2) 2',3'-dideoxycytidine 5'-diphosphate-rac-1-S-octadecyl-2-O-palmitoyl-1-thioglycerol (3), and AZT 5'-diphosphate-rac-1-O-tetradecyl-2-O-palmitoylglycerol (4). The conjugates form micelles by sonication (mean diameters ranging 6.8-55.5 nm). Conjugate 1 protected 80% of HIV-infected CEM cells as low as 0.58 microM and lost the protection at 180 microM due to prevailing cytotoxicity, while the conjugate started to show the cytotoxicity at 100 microM. Pharmacokinetics studies showed a significant increase of half-life values (t1/2) of AZT and AZddU2 (respective t1/2 = 5.69 and 6.5 h) after administration of conjugates 1 and 2, while those after administration of AZT and AZddU were 0.28 and 0.89 h, respectively. The fractions of the prodrugs 1 and 2 converted to the parent compounds AZT and AZddU were 36% and 55%, respectively.
3.Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine.
Chu CK;Bhadti VS;Doshi KJ;Etse JT;Gallo JM;Boudinot FD;Schinazi RF J Med Chem. 1990 Aug;33(8):2188-92.
A significant number of patients with AIDS and AIDS-related complex develop neurological complications. Therefore, it is critical that anti-HIV agents penetrate the blood-brain barrier and suppress viral replication in the brain. In an effort to increase the brain delivery of anti-HIV nucleosides, in vitro and in vivo pharmacokinetics of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine (AzddU, AZDU, or CS-87) and 3'-azido-3'-deoxythymidine (AZT, Zidovudine) have been studied. In vitro studies of the prodrugs (AzddU-DHP and AZT-DHP) in human serum, mouse serum, and mouse brain homogenate indicated that the rates of serum conversion from prodrugs to parent drugs are species dependent: mouse brain homogenate greater than mouse serum greater than human serum. Half-lives in human serum, mouse serum, and mouse brain homogenate are 4.33, 0.56, 0.17 h, respectively, for AzddU and 7.70, 1.40, and 0.18 h, respectively, for AZT. In vivo studies of AzddU-DHP and AZT-DHP showed that the prodrugs have areas under the serum concentration-time curves (AUC) similar to those of the parent drugs. The AUC in serum for AzddU following prodrug administration is 25.79 micrograms h/mL, which is similar to the value of 25.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related DNA/RNA Synthesis Products


CAS 105118-14-7 Datelliptium chloride

Datelliptium chloride
(CAS: 105118-14-7)

Datelliptium chloride, derived from ellipticine, is a DNA-intercalating agent with good activity in murine tumor models over a broad range of doses.

CAS 87434-82-0 Dezaguanine Mesilate

Dezaguanine Mesilate
(CAS: 87434-82-0)

Dezaguanine is a new antipurine antimetabolite. Dezaguanine is a DNA synthesis inhibitor. It has significant activity against transplantable rodent solid tumors...

CAS 1609960-31-7 TH588

TH588
(CAS: 1609960-31-7)

TH588 selectively kill U2OS and other cancer cell lines with less toxic to several primary or immortalized cells.

CP-74667 mesylate
(CAS: 138808-71-6)

CP-74667 is a Type II DNA topoisomerase inhibitor originated by Pfizer. No development was reported for Bacterial infections in USA.

CAS 896705-16-1 BMH-21

BMH-21
(CAS: 896705-16-1)

BMH-21 is a potent small molecule DNA intercalator. BMH-21 binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.

CAS 152247-02-4 CP 80080

CP 80080
(CAS: 152247-02-4)

CP 80080, a quinolinecarboxylic acid derivative, has been found to influencing DNA cleavage slightly and could probably be used in th anticancer studies.

Tinostamustine Hydrochloride
(CAS: 1793059-58-1)

The hydrochloride salt form of Tinostamustine, a benzimidazol derivative, has been found to be a HDAC inhibitor and could probably be effective against sorts of...

TH287
(CAS: 1609960-30-6)

TH287 is a potent and selective MTH1 (NUDT1) inhibitor with IC50 of 0.8 nM.

Omaciclovir
(CAS: 124265-89-0)

This active molecular is a DNA-directed DNA polymerase inhibitor potentially originated by Medivir AB. Omaciclovir can be selectively phosphorylated by viral th...

BAY 56-3722
(CAS: 215604-74-3)

BAY 56-3722, a water-soluble camptothecin derivative, is a DNA-Intercalating drug that stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-d...

CAS 14892-97-8 SCR7 pyrazine

SCR7 pyrazine
(CAS: 14892-97-8)

SCR7 pyrazine is a DNA Ligase IV inhibitor. SCR7 pyrazine has been shown to potentiate CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro u...

Pyridostatin TFA salt
(CAS: 1472611-44-1)

Pyridostatin stabilizes G-quadruplexes (G4s) in cells and elicits a DNA damage response by causing the formation of DNA double strand breaks (DSB).

CAS 1138549-36-6 CX-5461

CX-5461
(CAS: 1138549-36-6)

CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA with IC50 of 142 nM, has no effect on Pol II, and possesses 2...

CAS 127759-89-1 Lobucavir

Lobucavir
(CAS: 127759-89-1)

Lobucavir is a RNA-directed DNA polymerase inhibitor originated by Bristol-Myers Squibb as a nucleoside analog. Treatment for Cytomegalovirus infections, Hepati...

BRD7116
(CAS: 329059-55-4)

BRD7116, a bis-aryl sufone with cell-non-autonomous anti-leukemia activity, competitively binds to bacterial DNA gyrase and is an inhibitor of leukemia stem cel...

CAS 4533-39-5 Nitracrine

Nitracrine
(CAS: 4533-39-5)

Nitracrine, an acridine derivative, inhibits RNA synthesis and is an antitumor drug that has been used clinically for several years.

CAS 84472-85-5 Navuridine

Navuridine
(CAS: 84472-85-5)

Navuridine is a RNA-directed DNA polymerase inhibitor under the development of Bayer HealthCare Pharmaceuticals. But research for the teatment of HIV infections...

CAS 129716-45-6 MS-073

MS-073
(CAS: 129716-45-6)

MS-073 is a Type II DNA topoisomerase inhibitor under the development of Nihon Schering. MS-073 can overcome MDR in vitro and in vivo compare to verapamil. MS-0...

TH287 hydrochloride
(CAS: 1638211-05-8)

TH287 hydrochloride, with potent anti-cancer property, is a novel inhibitor of the MTH1 protein which is required for cancer cell survival and is overexpressed ...

CAS 841301-32-4 Amenamevir

Amenamevir
(CAS: 841301-32-4)

Amenamevir is a DNA helicase-primase inhibitors. It has anti-HSV activity against herpes simplex keratitis. In Mar 2016, Mahuro completed a phase III trial in H...

Chemical Structure

CAS 84472-85-5 Navuridine

Quick Inquiry

Verification code

Featured Items